Turning killer into cure -- the story of oncolytic herpes simplex viruses
- PMID: 26645902
Turning killer into cure -- the story of oncolytic herpes simplex viruses
Abstract
Viruses have the intrinsic capability to kill host cells. Even when the initial infection consists of only a few viruses, they can reproduce themselves in large quantities within a short time and quickly spread to nearby cells, causing substantial tissue damage. These same infectious properties become desirable if they can be converted into killer agents with specificity for malignant cells. Cancer virotherapy is doing exactly that by modifying viruses in ways that allow them to replicate in malignant cells but not in normal cells. Although relatively young, the field has seen significant progress in recent years. For example, the most recent phase III trial data on a herpes simplex virus (HSV)-based oncolytic virus (T-VEC) show substantial improvement in objective and durable responses over the control arm in melanoma patients, prompting speculation that a virotherapy may receive FDA approval for clinical use in the very near future. This review focuses on HSV-based oncolytic viruses, from their early history to their most recent development, with discussion of promising directions for further improvement.
Similar articles
-
Advance in herpes simplex viruses for cancer therapy.Sci China Life Sci. 2013 Apr;56(4):298-305. doi: 10.1007/s11427-013-4466-4. Epub 2013 Apr 7. Sci China Life Sci. 2013. PMID: 23564184 Review.
-
The molecular basis of herpesviruses as oncolytic agents.Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. doi: 10.2174/138920112800958931. Curr Pharm Biotechnol. 2012. PMID: 21740356 Review.
-
Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.Curr Pharm Biotechnol. 2012 Jul;13(9):1773-85. doi: 10.2174/138920112800958832. Curr Pharm Biotechnol. 2012. PMID: 21740353 Review.
-
Oncolytic Virotherapy by HSV.Adv Exp Med Biol. 2018;1045:63-84. doi: 10.1007/978-981-10-7230-7_4. Adv Exp Med Biol. 2018. PMID: 29896663 Review.
-
Targeted oncolytic herpes simplex viruses for aggressive cancers.Curr Pharm Biotechnol. 2012 Jul;13(9):1786-94. doi: 10.2174/138920112800958751. Curr Pharm Biotechnol. 2012. PMID: 21740360 Review.
Cited by
-
Advances in Immunotherapy for Melanoma: A Comprehensive Review.Mediators Inflamm. 2017;2017:3264217. doi: 10.1155/2017/3264217. Epub 2017 Aug 1. Mediators Inflamm. 2017. PMID: 28848246 Free PMC article. Review.
-
Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles.Oncotarget. 2018 Apr 20;9(30):21348-21358. doi: 10.18632/oncotarget.25096. eCollection 2018 Apr 20. Oncotarget. 2018. PMID: 29765544 Free PMC article.
-
Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.Oncotarget. 2016 Sep 20;7(38):61601-61618. doi: 10.18632/oncotarget.11202. Oncotarget. 2016. PMID: 27533247 Free PMC article.
-
Intravenous Injections of a Rationally Selected Oncolytic Herpes Virus as a Potent Virotherapy for Hepatocellular Carcinoma.Mol Ther Oncolytics. 2019 Oct 1;15:153-165. doi: 10.1016/j.omto.2019.09.004. eCollection 2019 Dec 20. Mol Ther Oncolytics. 2019. PMID: 31720372 Free PMC article.
-
Emerging nanotechnologies for cancer immunotherapy.Exp Biol Med (Maywood). 2016 May;241(10):1116-26. doi: 10.1177/1535370216647123. Epub 2016 May 4. Exp Biol Med (Maywood). 2016. PMID: 27190253 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources